e-Drug3D

2181

SEVABERTINIB

INN
SEVABERTINIB

cas 2521285-05-0

CLASS

ANTINEOPLASTIC
EGFR KINASE INHIBITOR
TREATMENT OF NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)

ROUTE (list)

ORAL

ATC code

L01EH06

PK parameters

Tmax 2 HOUR
VD 28 LITER
Cl 3.1 LITER / HOUR
PPB 95 PERCENT
t1/2 8 HOUR

Solubility

PRACTICALLY INSOLUBLE IN WATER

Target

TARGET EGFR

PDB
9QXN (CRYSTAL STRUCTURE OF WILD-TYPE EGFR IN COMPLEX WITH THE REVERSIBLE INHIBITOR SEVABERTINIB (BAY 2927088))

Download experimental 3D coordinates of A1JBI with added hydrogens

Download SDF file

4H-Pyrrolo[3,2-c]pyridin-4-one, 3-[(3-chloro-2-methoxyphenyl)amino]-2-[3-[(2S)-1,4-dioxan-2-ylmethoxy]-4-pyridinyl]-1,5,6,7-tetrahydro-

Formula:
C24H25ClN4O5

Calculated chemical properties:

MW 484.93
NB_atoms 34
XLogP 3.56
PSA 109.604
NB_HD 3
NB_HA 9
fsp3 0.33
Lipinski(0=no;1=yes) 1

FDA
NDA 219972 (label) INN (SEVABERTINIB) HYRNUO (BAYER HEALTHCARE) APPROVAL= AP YEAR= 2025 NEWMOLECULARENTITY